Researchers at Insilico Medicine, BioAge Labs, and academic partners present a standardized protocol to integrate mouse lifespan studies into IND-enabling preclinical programs. By running parallel lifespan assays during the 12-month development window, drug developers can detect geroprotective effects or long-term risks, enhancing the safety and efficacy profile of candidate therapeutics.
Key points
- Standardized mouse lifespan protocol integrated into IND-enabling preclinical studies.
- Collaboration among Insilico Medicine, BioAge Labs, and academic researchers to harmonize methods.
- Parallel lifespan and healthspan assessments reveal geroprotective effects and long-term risks.
Why it matters: Standardizing mouse lifespan studies promises to reveal aging impacts of drug candidates, guiding safer, more effective therapies and geroprotector discovery.
Q&A
- What is an IND-enabling study?
- Why use mice for lifespan studies?
- What are geroprotectors?
- How do lifespan and healthspan differ?